MacroGenics/MGNX

$17.26

2.67%
-
1D1W1MYTD1YMAX

About MacroGenics

MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.

Ticker

MGNX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Scott Koenig

Employees

357

Headquarters

Rockville, United States

MacroGenics Metrics

BasicAdvanced
$1.13B
Market cap
22.73
P/E ratio
$0.80
EPS
2.11
Beta
-
Dividend rate

What the Analysts think about MacroGenics

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 9 analysts.
14.37% downside
High $20.00
Low $11.00
$17.26
Current price
$14.78
Average price target

MacroGenics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
169.9% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$10.3M
-21.37%
Net income
$17.5M
-69.51%
Profit margin
169.9%
-61.22%

MacroGenics Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 392.89%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
$0.21
-$0.61
$0.92
$0.28
-
Expected
$0.10
$0.45
-$0.52
-$0.10
-$0.15
Surprise
105.7%
-234.9%
-276.51%
-392.89%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell MacroGenics stock

Buy or sell MacroGenics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing